口服降糖药领域的“孤勇者”华领医药,去年交出了一份完美答卷。3月27日,华领医药披露了2024年年报:年销售收入为2.559亿元,较2023年同期增加234%;其他收入约为1.168亿元。华领的销售收入全部来自于降糖药华堂宁®。去年是华堂宁进入国家医保目录销售的第一个完整年份,医保放量效应非常明显,带动公司营收大幅增长。目前,华堂宁®已经覆盖了全国约2700家医院,使用人群由2023年年末的2万人...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.